.png)
In investing, timing and momentum are crucial.
This is even more true in the DeepTech sector.
Investing early not only allows investors to benefit from reasonable valuations, but also to maximize return potential by making full use of leverage effects. Here's why.
DeepTech startups, particularly at the early stage, tend to have modest initial valuations compared to their potential. This is explained by several factors:
Early investment in these companies offers a particularly attractive growth outlook. Deep Tech companies systematically target large-scale markets with disruptive solutions. This combination opens the door to exponential growth, unmatched in other sectors.
Solid assets that reinforce value
A major advantage of Deep Tech companies lies in their intellectual assets:
These assets grow stronger and more valuable as the company develops, helping secure the initial investment.
The French Deep Tech ecosystem offers particularly interesting non-dilutive leverage opportunities:
Contrary to popular belief, Deep Tech companies can offer exit opportunities faster than one might expect. Technological maturity can quickly attract the interest of large corporations, creating exit opportunities as early as the following funding rounds.
An evolving participation strategy
Investing early also allows investors to:
The first-mover advantage in Deep Tech investing isn't simply a matter of valuation. It's a combination of strategic advantages that maximizes return potential while contributing to the emergence of innovative solutions for society.
For savvy investors, this approach represents a unique opportunity to combine financial performance with positive impact, all while benefiting from the best possible entry conditions.
Example: CXS Therapeutics' valuation was multiplied by more than 3.5x between its December 2023 funding round and its December 2024 round.
Learn more about CXS Therapeutics: see Le Journal Valeureux.
Gaining exposure to CXS Therapeutics: since both funding rounds are now closed, you can still gain exposure to CXS Therapeutics by investing directly in the Valeureux fund.